Authors:
KLEIMAN NS
GRAZIADEI N
LANCE E
MARESH K
TAYLOR J
HIGGINBOTHAM J
EDWARDS A
EFFRON MB
MASCELLI MA
JORDAN RE
Citation: Ns. Kleiman et al., SYNERGY OF ABCIXIMAB AND TICLOPIDINE IN PATIENTS UNDERGOING INTRACORONARY STENTING, Journal of the American College of Cardiology, 31(2), 1998, pp. 238-238
Authors:
KLEIMAN NS
MASCELLI MA
GRAZIADEI N
MARESH K
EDWARDS A
BAYSINGER L
FISCHER A
LANCE E
CABOT C
JORDAN R
Citation: Ns. Kleiman et al., TICLOPIDINE POTENTIATES ABCIXIMABS ABILITY TO INHIBIT ADP-INDUCED PLATELET-AGGREGATION IN-VITRO, Journal of the American College of Cardiology, 29(2), 1997, pp. 97486-97486
Authors:
WAGNER C
MACE K
MASCELLI MA
DERITA R
LANCE E
WEISMAN H
GHRAYEB J
JORDAN R
Citation: C. Wagner et al., PHARMACODYNAMICS OF REOPRO (C7E3 FAB) - FREE PLASMA-LEVELS DETERMINE CLINICAL EFFICACY, Thrombosis and haemostasis, 1997, pp. 26-26
Citation: E. Lance et Gk. Kaleh, A DIVERSITY SCHEME FOR A PHASE-COHERENT FREQUENCY-HOPPING SPREAD-SPECTRUM SYSTEM, IEEE transactions on communications, 45(9), 1997, pp. 1123-1129
Authors:
COLEMAN L
GOLDSCHMIDTCLERMONT PJ
LANCE E
MASCELLI MA
BRAY PF
Citation: L. Coleman et al., ABCIXIMAB (REOPRO) INHIBITION OF PLATELET-AGGREGATION AND GPIIB-IIIA RECEPTOR DENSITY ARE INDEPENDENT OF P1(A) (HPA-1) GENOTYPE, Blood, 90(10), 1997, pp. 3003-3003
Authors:
LANCE E
JORDAN B
PRESTON A
MACE K
SCHAIBLE T
MASCELLI MA
Citation: E. Lance et al., RECRUITMENT OF PREEXISTING ANTI-FAB IMMUNOGLOBULINS TO PLATELETS DOESNOT AFFECT THE SAFETY, PHARMACOKINETICS OR PHARMACODYNAMICS OF REOPRO(TM), Blood, 86(10), 1995, pp. 3594-3594
Authors:
WAGNER CL
KNIGHT D
MCALEER MF
LANCE E
MATTIS J
COLLER B
WEISMAN HF
JORDAN RE
Citation: Cl. Wagner et al., IMMUNOLOGICAL COMPARISON OF MURINE AND CHIMERIC 7E3 FAB FRAGMENTS IN HUMAN CLINICAL-TRIALS, The Journal of immunology, 150(8), 1993, pp. 158-158